SCHEMBL1378065

SCHEMBL1378065

Cc1ccc(OCCOc2cccc(-n3cnc4cc(C(=O)NCc5cccnc5)ccc43)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 5/20 0.56
TDP1 Q9NUW8 1/20 0.56
MMP13 P45452 1/20 0.55
TSHR P16473 2/20 0.55
KMT2A Q03164 2/20 0.52
LMNA P02545 2/20 0.52
MAPK1 P28482 1/20 0.52
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 1/20 0.50
RECQL P46063 1/20 0.50
POLB P06746 1/20 0.48
GAA P10253 1/20 0.48
PIK3CA P42336 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
BLM P54132 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1382911 0.98 TP53 (0.56) TP53TDP1MMP13TSHRKMT2A
SCHEMBL1377246 0.94 TP53 (0.64) TP53TDP1MMP13TSHRKMT2A
SCHEMBL1381085 0.93 TSHR (0.53) TP53TDP1TSHRKMT2ALMNA
SCHEMBL4489419 0.93 HTT (0.56) TP53TDP1MMP13TSHRKMT2A
SCHEMBL4499696 0.93 TSHR (0.52) TP53TDP1TSHRKMT2ALMNA
SCHEMBL1382294 0.92 LMNA (0.59) TP53TDP1MMP13KMT2ALMNA
SCHEMBL1379838 0.92 HTT (0.57) TP53TDP1TSHRKMT2ALMNA
SCHEMBL1377983 0.92 TSHR (0.52) TP53TDP1MMP13TSHRKMT2A
SCHEMBL1379156 0.91 TSHR (0.52) TP53TDP1TSHRKMT2ALMNA
SCHEMBL1378314 0.90 HTT (0.55) TP53TDP1MMP13TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4769720-B2 2011-09-07 JP claimed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US claimed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP claimed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO claimed
US-7521448-B2 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors OSI PHARMACEUTICALS, INC. 2006-08-24 US disclosed
EP-1664021-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI Pharmaceuticals, Inc. (US) 2006-06-07 EP disclosed
WO-2005021531-A1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2005-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189629-A1 N-substituted benzimidazolyl c-Kit inhibitors KIT, CHUK, TNNI3K TP53 119/4885TDP1 3696/4885MMP13 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.